BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Singh S, Osna NA, Kharbanda KK. Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. World J Gastroenterol 2017; 23(36): 6549-6570 [PMID: 29085205 DOI: 10.3748/wjg.v23.i36.6549] [Cited by in CrossRef: 81] [Cited by in F6Publishing: 65] [Article Influence: 20.3] [Reference Citation Analysis]
Number Citing Articles
1 Lachiondo-Ortega S, Mercado-Gómez M, Serrano-Maciá M, Lopitz-Otsoa F, Salas-Villalobos TB, Varela-Rey M, Delgado TC, Martínez-Chantar ML. Ubiquitin-Like Post-Translational Modifications (Ubl-PTMs): Small Peptides with Huge Impact in Liver Fibrosis. Cells 2019;8:E1575. [PMID: 31817258 DOI: 10.3390/cells8121575] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
2 Ok DP, Ko K, Bae JY. Exercise without dietary changes alleviates nonalcoholic fatty liver disease without weight loss benefits. Lipids Health Dis 2018;17:207. [PMID: 30172252 DOI: 10.1186/s12944-018-0852-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
3 Chen LJ, Lin XX, Guo J, Xu Y, Zhang SX, Chen D, Zhao Q, Xiao J, Lian GH, Peng SF, Guo D, Yang H, Shu Y, Zhou HH, Zhang W, Chen Y. Lrp6 Genotype affects Individual Susceptibility to Nonalcoholic Fatty Liver Disease and Silibinin Therapeutic Response via Wnt/β-catenin-Cyp2e1 Signaling. Int J Biol Sci 2021;17:3936-53. [PMID: 34671210 DOI: 10.7150/ijbs.63732] [Reference Citation Analysis]
4 Zhao R, Xiang B, Dolinsky VW, Xia M, Shen GX. Saskatoon berry powder reduces hepatic steatosis and insulin resistance in high fat-high sucrose diet-induced obese mice. J Nutr Biochem 2021;95:108778. [PMID: 34004342 DOI: 10.1016/j.jnutbio.2021.108778] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Arumugam MK, Paal MC, Donohue TM Jr, Ganesan M, Osna NA, Kharbanda KK. Beneficial Effects of Betaine: A Comprehensive Review. Biology (Basel) 2021;10:456. [PMID: 34067313 DOI: 10.3390/biology10060456] [Reference Citation Analysis]
6 Rashed ZE, Grasselli E, Khalifeh H, Canesi L, Demori I. Brown-Algae Polysaccharides as Active Constituents against Nonalcoholic Fatty Liver Disease. Planta Med 2020. [PMID: 33142346 DOI: 10.1055/a-1273-3159] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Patel F, Parwani K, Patel D, Mandal P. Metformin and Probiotics Interplay in Amelioration of Ethanol-Induced Oxidative Stress and Inflammatory Response in an In Vitro and In Vivo Model of Hepatic Injury. Mediators Inflamm 2021;2021:6636152. [PMID: 33953643 DOI: 10.1155/2021/6636152] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Alsherbiny MA, Abd-Elsalam WH, El Badawy SA, Taher E, Fares M, Torres A, Chang D, Li CG. Ameliorative and protective effects of ginger and its main constituents against natural, chemical and radiation-induced toxicities: A comprehensive review. Food Chem Toxicol 2019;123:72-97. [PMID: 30352300 DOI: 10.1016/j.fct.2018.10.048] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
9 Shi T, Wu L, Ma W, Ju L, Bai M, Chen X, Liu S, Yang X, Shi J. Nonalcoholic Fatty Liver Disease: Pathogenesis and Treatment in Traditional Chinese Medicine and Western Medicine. Evid Based Complement Alternat Med 2020;2020:8749564. [PMID: 31998400 DOI: 10.1155/2020/8749564] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 13.0] [Reference Citation Analysis]
10 Lam S, Doran S, Yuksel HH, Altay O, Turkez H, Nielsen J, Boren J, Uhlen M, Mardinoglu A. Addressing the heterogeneity in liver diseases using biological networks. Brief Bioinform 2021;22:1751-66. [PMID: 32201876 DOI: 10.1093/bib/bbaa002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
11 Subramaniyan V, Chakravarthi S, Jegasothy R, Seng WY, Fuloria NK, Fuloria S, Hazarika I, Das A. Alcohol-associated liver disease: A review on its pathophysiology, diagnosis and drug therapy. Toxicol Rep 2021;8:376-85. [PMID: 33680863 DOI: 10.1016/j.toxrep.2021.02.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Schwabe RF, Luedde T. Apoptosis and necroptosis in the liver: A matter of life and death. Nat Rev Gastroenterol Hepatol. 2018;15:738-752. [PMID: 30250076 DOI: 10.1038/s41575-018-0065-y] [Cited by in Crossref: 132] [Cited by in F6Publishing: 128] [Article Influence: 66.0] [Reference Citation Analysis]
13 Köseoğlu D, Koparal SS, Özdemir Başer Ö, Berker D. Exenatide improves cardiovascular risk factors in obese patients with type 2 diabetes mellitus: a prospective study. Turk J Med Sci 2021;51:167-74. [PMID: 32892547 DOI: 10.3906/sag-2004-154] [Reference Citation Analysis]
14 Kirpich IA, Warner DR, Feng W, Joshi-Barve S, McClain CJ, Seth D, Zhong W, Zhou Z, Osna NA, Kharbanda KK. Mechanisms, biomarkers and targets for therapy in alcohol-associated liver injury: From Genetics to nutrition: Summary of the ISBRA 2018 symposium. Alcohol 2020;83:105-14. [PMID: 31129175 DOI: 10.1016/j.alcohol.2019.05.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
15 Xue C, Gu X, Li G, Bao Z, Li L. Mitochondrial Mechanisms of Necroptosis in Liver Diseases. Int J Mol Sci 2020;22:E66. [PMID: 33374660 DOI: 10.3390/ijms22010066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
16 Chatterjee S, Patra D, Chakraborti U, Sengupta D, Ghosh P, Basu A, Sadhukhan GC, Chowdhury KD. Association of p38MAPK‐p53‐Fas aggregation in S‐allyl cysteine mediated regulation of hepatocarcinoma. Environmental Toxicology 2019;34:928-40. [DOI: 10.1002/tox.22764] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Wang R, Mu J. Arbutin attenuates ethanol-induced acute hepatic injury by the modulation of oxidative stress and Nrf-2/HO-1 signaling pathway. J Biochem Mol Toxicol 2021;:e22872. [PMID: 34346143 DOI: 10.1002/jbt.22872] [Reference Citation Analysis]
18 Sun J, Li B, Sun A, Zhao K, Ma Y, Zhao J, Pan H, Song Q, Wang Y, Yu C, Wang C, Zhang H, Zhang W, Kong C. Comprehensive analysis of aberrantly expressed profiles of messenger RNA in alcoholic liver disease. J Cell Biochem 2019;120:4248-54. [PMID: 30294942 DOI: 10.1002/jcb.27710] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Li Z, Wang F, Liang B, Su Y, Sun S, Xia S, Shao J, Zhang Z, Hong M, Zhang F, Zheng S. Methionine metabolism in chronic liver diseases: an update on molecular mechanism and therapeutic implication. Signal Transduct Target Ther 2020;5:280. [PMID: 33273451 DOI: 10.1038/s41392-020-00349-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
20 Federico A, Dallio M, Masarone M, Gravina AG, Di Sarno R, Tuccillo C, Cossiga V, Lama S, Stiuso P, Morisco F, Persico M, Loguercio C. Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients. Oxid Med Cell Longev 2019;2019:8742075. [PMID: 31737175 DOI: 10.1155/2019/8742075] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
21 Hsu MF, Koike S, Mello A, Nagy LE, Haj FG. Hepatic protein-tyrosine phosphatase 1B disruption and pharmacological inhibition attenuate ethanol-induced oxidative stress and ameliorate alcoholic liver disease in mice. Redox Biol 2020;36:101658. [PMID: 32769011 DOI: 10.1016/j.redox.2020.101658] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
22 Östlund C, Hernandez-Ono A, Shin JY. The Nuclear Envelope in Lipid Metabolism and Pathogenesis of NAFLD. Biology (Basel) 2020;9:E338. [PMID: 33076344 DOI: 10.3390/biology9100338] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Hung YH, Kanke M, Kurtz CL, Cubitt RL, Bunaciu RP, Zhou L, White PJ, Vickers KC, Hussain MM, Li X, Sethupathy P. MiR-29 Regulates de novo Lipogenesis in the Liver and Circulating Triglyceride Levels in a Sirt1-Dependent Manner. Front Physiol 2019;10:1367. [PMID: 31736786 DOI: 10.3389/fphys.2019.01367] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
24 Kaufmann B, Reca A, Kim AD, Feldstein AE. Novel Mechanisms for Resolution of Liver Inflammation: Therapeutic Implications. Semin Liver Dis 2021;41:150-62. [PMID: 34107544 DOI: 10.1055/s-0041-1723031] [Reference Citation Analysis]
25 Colica C, Boccuto L, Abenavoli L. Silymarin: An option to treat non-alcoholic fatty liver disease. World J Gastroenterol 2017; 23(47): 8437-8438 [PMID: 29309065 DOI: 10.3748/wjg.v23.i47.8437] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
26 Mello A, Hsu MF, Koike S, Chu B, Cheng J, Yang J, Morisseau C, Torok NJ, Hammock BD, Haj FG. Soluble Epoxide Hydrolase Hepatic Deficiency Ameliorates Alcohol-Associated Liver Disease. Cell Mol Gastroenterol Hepatol 2021;11:815-30. [PMID: 33068774 DOI: 10.1016/j.jcmgh.2020.10.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Sodum N, Kumar G, Bojja SL, Kumar N, Rao CM. Epigenetics in NAFLD/NASH: Targets and therapy. Pharmacol Res 2021;167:105484. [PMID: 33771699 DOI: 10.1016/j.phrs.2021.105484] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
28 Kwong EK, Puri P. Gut microbiome changes in Nonalcoholic fatty liver disease & alcoholic liver disease. Transl Gastroenterol Hepatol 2021;6:3. [PMID: 33409398 DOI: 10.21037/tgh.2020.02.18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
29 Jain D, Torres R, Celli R, Koelmel J, Charkoftaki G, Vasiliou V. Evolution of the liver biopsy and its future. Transl Gastroenterol Hepatol 2021;6:20. [PMID: 33824924 DOI: 10.21037/tgh.2020.04.01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Parizadeh SM, Parizadeh SA, Alizade-noghani M, Jafarzadeh-esfehani R, Ghandehari M, Mottaghi-moghaddam A, Goldani F, Khazaei M, Ghayour-mobarhan M, Ferns GA, Hassanian SM, Avan A. Association between non-alcoholic fatty liver disease and colorectal cancer. Expert Review of Gastroenterology & Hepatology 2019;13:633-41. [DOI: 10.1080/17474124.2019.1617696] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
31 Yang JY, Li M, Zhang CL, Liu D. Pharmacological properties of baicalin on liver diseases: a narrative review. Pharmacol Rep 2021;73:1230-9. [PMID: 33595821 DOI: 10.1007/s43440-021-00227-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
32 Gala KS, Vatsalya V. Emerging Noninvasive Biomarkers, and Medical Management Strategies for Alcoholic Hepatitis: Present Understanding and Scope. Cells 2020;9:E524. [PMID: 32106390 DOI: 10.3390/cells9030524] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
33 Han SW, Wang XJ, Cui BS, Sun H, Chen H, Ferreira D, Li S, Hamann MT. Hepatoprotective Glucosyloxybenzyl 2-Hydroxy-2-isobutylsuccinates from Pleione yunnanensis. J Nat Prod 2021;84:738-49. [PMID: 33606538 DOI: 10.1021/acs.jnatprod.0c01117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Li Y, Wang C, Jin Y, Chen H, Cao M, Li W, Luo H, Wu Z. Huang-Qi San improves glucose and lipid metabolism and exerts protective effects against hepatic steatosis in high fat diet-fed rats. Biomed Pharmacother 2020;126:109734. [PMID: 32114355 DOI: 10.1016/j.biopha.2019.109734] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
35 Tavakoli T, Zarban A, Hooshyar R, Salmani F, Tajik H. Improvement of thiol groups and total antioxidant capacity in patients with non-alcoholic fatty liver after treatment with pioglitazone. Arch Physiol Biochem 2020;:1-5. [PMID: 32608271 DOI: 10.1080/13813455.2020.1784953] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Kamboj P, Sarkar S, Gupta SK, Bisht N, Kumari D, Alam MJ, Barge S, Kashyap B, Deka B, Bharadwaj S, Rahman S, Dutta PP, Borah JC, Talukdar NC, Banerjee SK, Kumar Y. Methanolic Extract of Lysimachia Candida Lindl. Prevents High-Fat High-Fructose-Induced Fatty Liver in Rats: Understanding the Molecular Mechanism Through Untargeted Metabolomics Study. Front Pharmacol 2021;12:653872. [PMID: 33935766 DOI: 10.3389/fphar.2021.653872] [Reference Citation Analysis]
37 Cholankeril G, Gadiparthi C, Yoo ER, Dennis BB, Li AA, Hu M, Wong K, Kim D, Ahmed A. Temporal Trends Associated With the Rise in Alcoholic Liver Disease-related Liver Transplantation in the United States. Transplantation 2019;103:131-9. [PMID: 30300285 DOI: 10.1097/TP.0000000000002471] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
38 Jung I, Kim H, Moon S, Lee H, Kim B. Overview of Salvia miltiorrhiza as a Potential Therapeutic Agent for Various Diseases: An Update on Efficacy and Mechanisms of Action. Antioxidants (Basel) 2020;9:E857. [PMID: 32933217 DOI: 10.3390/antiox9090857] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
39 Gao Y, Zhang S, Li J, Zhao J, Xiao Q, Zhu Y, Zhang J, Huang W. Effect and mechanism of ginsenoside Rg1-regulating hepatic steatosis in HepG2 cells induced by free fatty acid. Biosci Biotechnol Biochem 2020;84:2228-40. [PMID: 32654591 DOI: 10.1080/09168451.2020.1793293] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Jiang ZB, Gao J, Chai YH, Li W, Luo YF, Chen YZ. Astragaloside alleviates alcoholic fatty liver disease by suppressing oxidative stress. Kaohsiung J Med Sci 2021;37:718-29. [PMID: 33973356 DOI: 10.1002/kjm2.12390] [Reference Citation Analysis]
41 Pan Q, Han T, Li G. Novel insights into the roles of tRNA-derived small RNAs. RNA Biol 2021;:1-11. [PMID: 33998370 DOI: 10.1080/15476286.2021.1922009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Albracht-Schulte K, Gonzalez S, Jackson A, Wilson S, Ramalingam L, Kalupahana NS, Moustaid-Moussa N. Eicosapentaenoic Acid Improves Hepatic Metabolism and Reduces Inflammation Independent of Obesity in High-Fat-Fed Mice and in HepG2 Cells. Nutrients 2019;11:E599. [PMID: 30871035 DOI: 10.3390/nu11030599] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
43 Ivashkin VT, Maevskaya MV, Shirokova EN, Maev IV, Samsonov AA, Sas EI, Palgova LK, Starostin K. Correlation of Objective Endpoints and Subjective Patient-Reported Outcomes in NAFLD Treatment with Essential Phospholipids: Real-World Data Based on Pooled Analysis of Observational Studies. Drugs Real World Outcomes 2021;8:369-82. [PMID: 33993460 DOI: 10.1007/s40801-021-00250-x] [Reference Citation Analysis]
44 Parra-Robert M, Casals E, Massana N, Zeng M, Perramón M, Fernández-Varo G, Morales-Ruiz M, Puntes V, Jiménez W, Casals G. Beyond the Scavenging of Reactive Oxygen Species (ROS): Direct Effect of Cerium Oxide Nanoparticles in Reducing Fatty Acids Content in an In Vitro Model of Hepatocellular Steatosis. Biomolecules 2019;9:E425. [PMID: 31470518 DOI: 10.3390/biom9090425] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
45 Shan MY, Dai Y, Ren XD, Zheng J, Zhang KB, Chen B, Yan J, Xu ZH. Berberine mitigates nonalcoholic hepatic steatosis by downregulating SIRT1-FoxO1-SREBP2 pathway for cholesterol synthesis. J Integr Med 2021;19:545-54. [PMID: 34686466 DOI: 10.1016/j.joim.2021.09.003] [Reference Citation Analysis]
46 Bai L, Li H. Innate immune regulatory networks in hepatic lipid metabolism. J Mol Med (Berl). 2019;97:593-604. [PMID: 30891617 DOI: 10.1007/s00109-019-01765-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 11.5] [Reference Citation Analysis]
47 Jeong MS, Park S, Han EJ, Park SY, Kim MJ, Jung K, Cho S, Kim S, Yoon W, Ahn G, Kim K. Pinus thunbergii PARL leaf protects against alcohol-induced liver disease by enhancing antioxidant defense mechanism in BALB/c mice. Journal of Functional Foods 2020;73:104116. [DOI: 10.1016/j.jff.2020.104116] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
48 Elnagdy M, Barve S, McClain C, Gobejishvili L. cAMP Signaling in Pathobiology of Alcohol Associated Liver Disease. Biomolecules 2020;10:E1433. [PMID: 33050657 DOI: 10.3390/biom10101433] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Dolin CE, Arteel GE. The Matrisome, Inflammation, and Liver Disease. Semin Liver Dis 2020;40:180-8. [PMID: 31910448 DOI: 10.1055/s-0039-3402516] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
50 Afsharinasab M, Mohammad-Sadeghipour M, Reza Hajizadeh M, Khoshdel A, Mirzaiey V, Mahmoodi M. The effect of hydroalcoholic Berberis integerrima fruits extract on the lipid profile, antioxidant parameters and liver and kidney function tests in patients with nonalcoholic fatty liver disease. Saudi J Biol Sci 2020;27:2031-7. [PMID: 32742180 DOI: 10.1016/j.sjbs.2020.04.037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
51 Zhao C, Liu L, Liu Q, Li F, Zhang L, Zhu F, Shao T, Barve S, Chen Y, Li X, McClain CJ, Feng W. Fibroblast growth factor 21 is required for the therapeutic effects of Lactobacillus rhamnosus GG against fructose-induced fatty liver in mice. Mol Metab. 2019;29:145-157. [PMID: 31668386 DOI: 10.1016/j.molmet.2019.08.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
52 Lu J, Zhu X, Zhang C, Lu F, Lu Z, Lu Y. Co-expression of alcohol dehydrogenase and aldehyde dehydrogenase in Bacillus subtilis for alcohol detoxification. Food and Chemical Toxicology 2020;135:110890. [DOI: 10.1016/j.fct.2019.110890] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
53 Lv Y, So KF, Xiao J. Liver regeneration and alcoholic liver disease. Ann Transl Med 2020;8:567. [PMID: 32775368 DOI: 10.21037/atm.2020.02.168] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Zhang H, Yang L, Wang Y, Huang W, Li Y, Chen S, Song G, Ren L. Oxymatrine alleviated hepatic lipid metabolism via regulating miR-182 in non-alcoholic fatty liver disease. Life Sci 2020;257:118090. [PMID: 32679144 DOI: 10.1016/j.lfs.2020.118090] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
55 Chen X, Bian M, Jin H, Lian N, Shao J, Zhang F, Zheng S. Dihydroartemisinin attenuates alcoholic fatty liver through regulation of lipin-1 signaling. IUBMB Life 2019;71:1740-50. [PMID: 31265202 DOI: 10.1002/iub.2113] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
56 Chang BY, Kim HJ, Kim TY, Kim SY. Enzyme-Treated Zizania latifolia Extract Protects against Alcohol-Induced Liver Injury by Regulating the NRF2 Pathway. Antioxidants (Basel) 2021;10:960. [PMID: 34203789 DOI: 10.3390/antiox10060960] [Reference Citation Analysis]
57 Ren J, Sha W, Shang S, Yuan E. Hepatoprotective peptides purified from Corbicula fluminea and its effect against ethanol‐induced LO2 cells injury. Int J Food Sci Technol 2021;56:352-61. [DOI: 10.1111/ijfs.14649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Kong L, Dong R, Huang K, Wang X, Wang D, Yue N, Wang C, Sun P, Gu J, Luo H, Liu K, Wu J, Sun H, Meng Q. Yangonin modulates lipid homeostasis, ameliorates cholestasis and cellular senescence in alcoholic liver disease via activating nuclear receptor FXR. Phytomedicine 2021;90:153629. [PMID: 34304130 DOI: 10.1016/j.phymed.2021.153629] [Reference Citation Analysis]
59 Yoon YH, Chen CM, Slater ME, Jung MK, White AM. Trends in Premature Deaths From Alcoholic Liver Disease in the U.S., 1999-2018. Am J Prev Med 2020;59:469-80. [PMID: 32863077 DOI: 10.1016/j.amepre.2020.04.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
60 Wang X, Chang X, Zhan H, Zhang Q, Li C, Gao Q, Yang M, Luo Z, Li S, Sun Y. Curcumin and Baicalin ameliorate ethanol-induced liver oxidative damage via the Nrf2/HO-1 pathway. J Food Biochem 2020;:e13425. [PMID: 32770697 DOI: 10.1111/jfbc.13425] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
61 Ramos LF, Silva CM, Pansa CC, Moraes KCM. Non-alcoholic fatty liver disease: molecular and cellular interplays of the lipid metabolism in a steatotic liver. Expert Rev Gastroenterol Hepatol 2021;15:25-40. [PMID: 32892668 DOI: 10.1080/17474124.2020.1820321] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
62 Cheng Q, Li YW, Yang CF, Zhong YJ, He H, Zhu FC, Li L. Methyl ferulic acid attenuates ethanol-induced hepatic steatosis by regulating AMPK and FoxO1 Pathways in Rats and L-02 cells. Chem Biol Interact 2018;291:180-9. [PMID: 29940154 DOI: 10.1016/j.cbi.2018.06.028] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
63 Kounakis K, Chaniotakis M, Markaki M, Tavernarakis N. Emerging Roles of Lipophagy in Health and Disease. Front Cell Dev Biol. 2019;7:185. [PMID: 31552248 DOI: 10.3389/fcell.2019.00185] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 22.0] [Reference Citation Analysis]
64 Fernandez-Travieso JC, Rodriguez-Perez I, Ruenes-Domech C, lIlnait-Ferrer J, Fernandez-Dorta L, Mendoza-Castano S. Benefits of the Therapy With Abexol in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology Res 2020;13:73-80. [PMID: 32362966 DOI: 10.14740/gr1273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Yang L, Liu Q, Zhang H, Wang Y, Li Y, Chen S, Song G, Ren L. Silibinin improves nonalcoholic fatty liver by regulating the expression of miR‑122: An in vitro and in vivo study. Mol Med Rep 2021;23:335. [PMID: 33760189 DOI: 10.3892/mmr.2021.11974] [Reference Citation Analysis]